Meanwhile, President Trump continues to push reciprocal levies and reshoring efforts, while pharma prepares for escalating costs.

As part of a growing trend of pharmaceutical giants reshoring their operations, AstraZeneca (AZN) announced Monday that it will invest $50 billion in U.S. manufacturing by 2030. This is the company’s ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

The pharmaceutical industry’s move toward increased U.S.-based manufacturing is changing the landscape of career ...

Gov. Glenn Youngkin says he has a deal for a multi-billion-dollar pharmaceutical factory in Virginia, but he doesn't have a ...

With a mega investment of 50 billion dollars, Astrazeneca has plans to expand its presence in medicines manufacturing and R&D ...

AstraZeneca, a pharmaceutical company, has announced its plans to bring a drug substance manufacturing facility to Virginia.

Phlow’s capital raise announcement came a day after Gov. Glenn Youngkin and British pharmaceutical firm AstraZeneca publicly ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

The $50 billion investment in the United States by AstraZeneca is just one of many significant investments expected from pharmaceutical companies as they react to President Donald Trump’s ...

AstraZeneca said it was investing €300m to establish a next-generation active pharmaceutical ingredient (API) manufacturing ...